Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663333 | 0.82 | PSIP1 (0.50) | CA2CA1THRBPTGES2 | |
| SCHEMBL10626704 | 0.81 | PTGS2 (0.56) | PTGS2PTGS1THRB | |
| SCHEMBL1290883 | 0.79 | KMT2A (0.49) | ALDH1A1NPC1MAPTPKMRAB9A | |
| SCHEMBL15108250 | 0.79 | PLA2G7 (0.49) | PTGS2SLC22A12PTGS1PKM | |
| SCHEMBL6658979 | 0.79 | CA2 (0.67) | PTGS2CA2CA1SLC22A12PTGS1 | |
| SCHEMBL16492686 | 0.78 | KMT2A (0.55) | PTGS2CA2CA1SLC22A12PTGS1 | |
| SCHEMBL4094789 | 0.78 | PTGS2 (0.44) | ALDH1A1PTGS2CA2CA1SLC22A12 | |
| SCHEMBL17703732 | 0.76 | NR3C1 (0.43) | ALDH1A1PTGS2SLC22A12PTGS1PKM | |
| SCHEMBL6662688 | 0.76 | KEAP1 (0.57) | CA2CA1 | |
| SCHEMBL1688371 | 0.76 | PLA2G7 (0.49) | PTGS2SLC22A12PTGS1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244615-B1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | US | disclosed |
| EP-1244615-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047873-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | DDT, PFAS, DAO | ALDH1A1 325/4885PTGS2 3174/4885CA2 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.